Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News RespireRx Pharmaceuticals Inc RSPI

RespireRx Pharmaceuticals Inc. develops treatments to combat disorders caused by disruption of neuronal signaling. The Company is developing treatment options that address conditions, such as obstructive sleep apnea (OSA), attention deficit hyperactivity disorder, epilepsy, acute and chronic pain, including inflammatory and neuropathic pain, and recovery from spinal cord injury (SCI), which are... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >

Current News (PINL:RSPI)

RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury

GlobeNewswire March 20, 2024

RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine

GlobeNewswire February 13, 2024

RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors

GlobeNewswire January 22, 2024

RespireRx Pharmaceuticals Inc. Announces the Publication of a Case Report in which KRM-II-81 Totally Suppressed Epileptiform Activity in Brain Tissue Surgically Removed from Epileptic Patient

GlobeNewswire January 4, 2024

RespireRx Pharmaceuticals Inc. Announces Agreement with Ponto Ventures to Drive Business Development with Will Clodfelter as RespireRx Part-Time Senior VP of Business Development

GlobeNewswire December 11, 2023

RespireRx Pharmaceuticals Inc.'s Subsidiary ResolutionRx Ltd Enters into Master Services Agreement for Dronabinol Manufacturing and Related Services

GlobeNewswire October 12, 2023

RespireRx Pharmaceuticals Inc. and ResolutionRx Ltd Enter into Bilateral Agreements to Establish ResolutionRx Ltd as an Operating Company

GlobeNewswire August 9, 2023

ResolutionRx Ltd, a Subsidiary of RespireRx Pharmaceuticals Inc., Enters into Letter of Intent with Cantheon Capital for the Financing of Anticipated Research and Development Costs

GlobeNewswire May 24, 2023

RespireRx Pharmaceuticals Inc. Establishes Research Collaboration With University College London to Study the Use of AMPAkines for the Treatment of GRIA Disorders

GlobeNewswire April 5, 2023

Opinion & Analysis (PINL:RSPI)

No current opinion is available.

Bullboard Posts (PINL:RSPI)

RespireRx Pharmaceuticals Inc. Announces the Appointment of

JUST IN: $RSPI RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of DirectorsGlen Rock, N.J...
whytestocks - January 22, 2024

Any Updates?

Anyone know anything about this stock?
zerogravity1 - May 18, 2020